Androgen
Danazol for Low Blood Counts in Liver Cirrhosis
This trial is testing danazol, a medication taken by mouth, to see if it can help people with liver disease and low blood cell counts. Danazol may work by changing hormone levels to increase blood cell production. It has been used to treat certain bleeding conditions, showing long-term benefits.
Thrombopoietin Receptor Agonist
Avatrombopag for Pediatric ITP
This trial is testing a medication called avatrombopag, which helps increase blood platelets. It targets children who have had low platelet counts for an extended period due to their immune system attacking these cells. The medication works by encouraging the body to make more platelets, which are important for stopping bleeding. Avatrombopag has been shown to increase platelet counts in patients with low platelet levels, including those with liver disease.
Monoclonal Antibodies
Efgartigimod for ITP
This trial is testing ARGX-113, a medication for adults with primary ITP, a condition where the immune system attacks platelets. The medication aims to calm the immune system to prevent it from attacking these important blood cells.
Bruton's Tyrosine Kinase Inhibitor
Pirtobrutinib for Immune Thrombocytopenic Purpura
"This trial aims to see how well pirtobrutinib is tolerated and what side effects may occur in patients with Primary Immune Thrombocytopenia. It will also investigate the
Popular Filters
Trials for Thrombocytopenic Purpura Patients
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Monoclonal Antibodies
PF-06835375 for Low Platelet Count
This trial uses a new injectable medicine called PF-06835375. It targets adults with long-lasting or chronic low platelet counts due to primary immune thrombocytopenia (ITP). The medicine works by reducing specific immune cells to help increase platelet counts.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Trials for TTP Patients
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Monoclonal Antibodies
PF-06835375 for Low Platelet Count
This trial uses a new injectable medicine called PF-06835375. It targets adults with long-lasting or chronic low platelet counts due to primary immune thrombocytopenia (ITP). The medicine works by reducing specific immune cells to help increase platelet counts.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Phase 3 Trials
Thrombopoietin Receptor Agonist
Eltrombopag vs Standard Treatment for ITP in Children
This trial tests eltrombopag, a drug that helps make more platelets, in children with a specific blood condition. The goal is to see if it works better than standard treatments.
Romiplostim for Chemotherapy-Induced Low Platelet Count
This trial tests romiplostim, a drug that boosts platelet production, in adults with certain cancers undergoing chemotherapy. It aims to help these patients maintain their chemotherapy schedule by increasing their platelet counts. Romiplostim has shown effectiveness in increasing platelet counts in patients with low platelet levels due to chemotherapy.
Monoclonal Antibodies
Efgartigimod for Low Platelet Count
This trial is testing a new injection treatment for adults whose immune systems destroy their own platelets. The treatment aims to calm the immune system to stop it from attacking these important blood cells. Romiplostim promotes platelet production and has been used in the treatment of this condition.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
This trial tests rilzabrutinib, a drug that may help people with chronic ITP who have very low platelet counts. The drug works by blocking a substance that causes the immune system to destroy platelets. Participants will take the drug for several months to see if it helps increase their platelet levels.
Trials With No Placebo
Platelet Transfusion
Platelet Transfusion Thresholds for Low Platelet Count in Premature Infants
"This trial aims to see if giving lower amounts of platelet transfusions to very premature babies can help them survive without experiencing severe bleeding up to a certain age."
Procedure
Pulsatile Blood Flow for Reducing Acute Kidney Injury
This trial aims to see if using a specific type of blood flow during heart surgery can help reduce the risk of kidney damage. Researchers will also look at how safe and effective this method is compared to the
Anticoagulant
Anticoagulation Strategies for Blood Clots in Cancer Patients
This trial is for cancer patients who have blood clots and low platelet counts. The investigators will compare two treatment strategies: full dose blood thinners with platelet transfusions or reduced dose blood thinners without transfusions.
Romiplostim for Lymphoma
This trial will study whether a drug called romiplostim can help treat low platelet count caused by standard chemotherapy for lymphoma, as well as whether it can prevent the need for chemotherapy dose delays, reductions, or platelet transfusions.
View More Related Trials
Frequently Asked Questions
Introduction to thrombocytopenia
What are the top hospitals conducting thrombocytopenia research?
In the realm of clinical trials focused on thrombocytopenia, several leading hospitals are making significant strides in improving treatments and outcomes for patients. One notable institution is the National Institutes of Health Clinical Center located in Bethesda. With four ongoing thrombocytopenia trials and a total of six conducted over time, this facility has been at the forefront of research since their first recorded trial in 2016. In New york City, Memorial Sloan Kettering Cancer Center (All Protocol Activities) is also dedicated to advancing knowledge in this field. Currently undertaking three active thrombocytopenia trials and having completed three historically, they initiated their inaugural trial as recently as 2020.
Additionally contributing to the progress against thrombocytopenia is Texas Children's Hospital situated in Houston. The hospital currently has three ongoing clinical trials for this condition while having already accomplished six previous investigations since embarking on its journey with a pioneering trial back in 2005. Meanwhile, American Oncology Partners of Maryland, PA based out of Bethesda focuses on addressing thrombocytopenia with an equal emphasis by conducting three active clinical tests and holding records for successfully finishing just as many prior endeavors; all starting from1993.
Lastly Massachusetts General Hospital Cancer Center based within Boston also actively participates with ongoing investigations closeby.They conduct similar number laboratory examinations being involved into researching regarding symptoms related to low platelet count showing alarming signs under category 'thrombo-cyto-penia' which was only brought forward during last two years bearing fruitful results.This included initiationof pathbreaking experimentsto take leaps fowards through exploring potential cures that can help patients suffering globally
These esteemed hospitals collectively showcase dedication towards understanding thrombocytopenia better so that innovative interventions can be developed to alleviate its severity and impact on individuals affected by this condition worldwide
Which are the best cities for thrombocytopenia clinical trials?
When it comes to thrombocytopenia clinical trials, several cities stand out for their ongoing research efforts. New york, New York and Bethesda, Maryland both have 12 active trials exploring treatments like Oral Azacitidine, Eltrombopag, Romiplostim, Avatrombopag, and PF-06835375. Boston, Massachusetts follows closely behind with 11 ongoing studies investigating Romiplostim, Experimental: Avatrombopag and PRN1008 among others. Additionally, Columbus Ohio and Philadelphia Pennsylvania each have 10 active trials focusing on treatments that include Experimental: Avatrombopag and Oral Azacitidine. These cities offer individuals with thrombocytopenia access to cutting-edge clinical trials aimed at finding new approaches to manage this condition effectively.
Which are the top treatments for thrombocytopenia being explored in clinical trials?
Thrombocytopenia, a condition characterized by low platelet count, is the focus of ongoing clinical trials exploring potential treatments. Leading the pack is romiplostim, which is currently being tested in four active trials for thrombocytopenia. Since its introduction in 2004, it has been involved in a total of 28 trials dedicated to addressing this condition. Another contender worth noting is avatrombopag, with two active and 19 all-time thrombocytopenia trials since its debut in 2009. The novel drug fostamatinib has also entered the scene with two ongoing studies focused on treating thrombocytopenia; it was first listed just recently in 2023. Additionally, whole blood transfusion shows promise as an emerging treatment option supported by one active trial specifically targeting thrombocytopenia since its listing also began in 2023. These innovative approaches offer hope for improving outcomes for individuals living with thrombocytopenia as research continues to progress.
What are the most recent clinical trials for thrombocytopenia?
Recent clinical trials have shown promising results in the treatment of thrombocytopenia, a condition characterized by low platelet counts. Avatromopag, povetacicept 240mg, Danazol Pill, Active, and fostamatinib have all been investigated for their efficacy in addressing this disorder. These trials encompassed various phases and were made accessible at different times throughout the year. The findings from these studies provide hope for improved management strategies to combat thrombocytopenia and ultimately enhance patient outcomes.
What thrombocytopenia clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of thrombocytopenia research. In March 2022, Veralox Therapeutics wrapped up a trial investigating the potential of VLX-1005 to address this condition. Bioverativ, a Sanofi company, completed their BIVV020 trial in February 2021, adding to our understanding of effective treatments for thrombocytopenia. Additionally, UCB Biopharma SRL concluded their Rozanolixizumab study in December 2020. These advancements mark important steps forward and offer hope for patients dealing with thrombocytopenia.